论文部分内容阅读
作者从一例急性粒细胞性白血病患者尿中分离并纯化了一种新的癌症相关糖蛋白EDC_1〔注〕,其分子量为27,000,含糖量高达27%,含半胧氨酸5%,并具有与各种已知的庙症相关抗原及血浆蛋白迥然不同的抗原性。EDC;只以痕迹出现在正常人尿中(用放射免疫方法测得含量<0.1毫克/天)。作者选择了8例癌症患者(卵巢腺癌2例、急性粒细胞性白血病3例、结肠腺癌1例、急性单核细胞性白血病1例、肺癌1例),研究了化疗对癌症相关糖蛋白EDC:在尿中排泄的影响。人院后第1一3周作了常规临床检查(如实体癌块的大小、腹水或胸腔渗出的情况、白血病病人的末稍血液和骨髓检查),并作治疗前尿EDC:的测定。然后用抗癌药进行化疗。
The authors isolated and purified a new cancer-associated glycoprotein, EDC_1, from the urine of a patient with acute myeloid leukemia that has a molecular weight of 27,000, a sugar content of 27%, a 5% hemi-amino acid, and a With a variety of known temple disease antigen and plasma proteins very different antigenicity. EDC; traces appear only in normal human urine (radioimmunoassay content <0.1 mg / day). The authors selected 8 cancer patients (ovarian adenocarcinoma in 2 cases, acute myeloid leukemia in 3 cases, colon adenocarcinoma in 1 case, acute monocytic leukemia in 1 case, lung cancer in 1 case) and studied the effects of chemotherapy on cancer-associated glycoproteins EDC: The effect of urinary excretion. Routine clinical examinations (such as size of solid tumor mass, exudation of ascites or pleural effusion, end-stage blood and bone marrow examination of leukemia patients) were performed at week 1 to week 3 after hospitalization and EDC was measured before treatment. Then use anticancer drugs for chemotherapy.